Advertisement

Topics

22nd Century Group Files 2017 Third Quarter Report and Announces Conference Call to Provide Business Update

16:20 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
22nd Century’s proprietary Very Low Nicotine cigarettes demonstrate that the FDA’s planned mandate for cigarettes with non-addictive levels of nicotine is both achievable and realistic. Leading regulatory expert, Dr...

Other Sources for this Article

22nd Century Group
James Vail, 716-270-1523
Director of Communications
jvail@xxiicentury.com

NEXT ARTICLE

More From BioPortfolio on "22nd Century Group Files 2017 Third Quarter Report and Announces Conference Call to Provide Business Update"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...